Результаты поиска

Increased Indoleamine 2, 3-Dioxygenase expression modulates Th1/Th17/Th22 and Treg pathway in humans with Helicobacter Pylori-Infected gastric mucosa.

Introduction and purposeIndoleamine 2, 3- dioxygenase (IDO) plays an importantrole in immunosuppressive pathway, as inhibits responsesof T cells and promotes immune tolerance. Host responsetoHelicobacter pylori (H. pylori) is involved in the infection persistenceand it is also associatedwith different clinical outcomes. The aim of this study was to investigate the role of IDO in H. pylori-infected patients with gastritis diseases and peptic ulcer diseases (PUD) through the assessment of the relationship among IDO protein expression and the numbers of T helper (Th)-1, Th17, Th22, and T regulato

Совпадение в полном тексте источника
… Thiessen</u>, Histocompatibility, Alberta Precision Laboratories, University of Alberta Hospitals, Edmonton, Alberta, CANADA|P. Campbell, A.M. … Berka, Histocompatibility and Immunogenetics Laboratory, Alberta Precision Laboratories, University of Calgary, Calgary, Alberta, CANADA|<u > A. ABU-KHADER</u>, F. Khan, N. …

A scoping review of breakthrough cancer pain: Multidimensional patient needs and influencing factors.

ObjectivesBreakthrough cancer pain (BTcP), a common complication among cancer patients, has been confirmed to have extensive impacts on patients' lives. However, existing research remains fragmented, lacking a systematic theoretical framework to integrate these findings. This scoping review aimed to systematically examine the multidimensional needs and influencing factors of BTcP patients based on Kolcaba's Comfort Theory, construct a conceptual mapping of BTcP needs and influences, and explore the theoretical foundations and practical pathways of related interventions.MethodsUsing a scoping r

Совпадение в полном тексте источника
… Palliative Care Service and One Hospice) Verify the circadian rhythm of breakthrough pain in Advanced Cancer Patients - Patient Personal Diaries: Recording breakthrough pain frequency, occurrence time, and rescue analgesia - Nurses and family members assist patients in recording to ensure accuracy - Alberta … Sites) - Assess prevalence and characteristics of breakthrough cancer pain (BTP) - Evaluate 1-month cumulative incidence of newly diagnosed BTP - Describe clinical characteristics of untreated BTP patients - Assess BTP impact on daily activities and quality of life - Davies Algorithm: BTP diagnosis - Alberta …

Abstracts of the 3rd International Conference on Cancer Cachexia, September 23–25, 2016 in Washington, DC, USA

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Highlights from the conference included our Keynote Speaker, Dr Vickie Baracos from the University of Alberta, a presentation from a patient advocate, Mr David Kochanczyk, and a special lecture from Dr Douglas Lowy, Director of the National Cancer Institute, USA. … Lee Moffitt Cancer Center, Tampa, Florida, USA; 2 University of Alberta Canada, Edmonton, Alberta, Canada Recent findings suggest that computed‐tomography (CT)–defined features of body composition (ie skeletal muscle, fat amount and distribution) predict for cancer‐associated survival. …

Прогресс, не зависящий от возобновления биологии в множестве склерозов: исследование реальных слов.

Прогресс, не зависящий от рецидивной активности (ИПРА), подразумевает развитие инвалидности у людей с повторно излучающимся множественным склерозом (RRMS) вторичного до нейродегенерации. Механистическая и биологическая ПИРА может повлиять на традиционное различие между прогрессивными и повторными СМС. В данном случае мы подсчитали прогресс, не зависящий от восстановления биологии (PIRB), в группе из 823 участников с клинически изолированным синдромом/RRMS в Калгари, Канада, с использованием модифицированного критерия [исключая рецидивы, подстрекательскую активность MRI, промежуточное ухудшение

Совпадение в полном тексте источника
… Materials and methods Study design and participants Three real-world RRMS cohorts were drawn from the Clinical Impact of Multiple Sclerosis (CIMS) ( 9 ), an ongoing observational study of MS patients at the University of Calgary (Alberta, Canada). … This research study was supported by funds to the Alberta Multiple Sclerosis Collaboration from the Ministry of Economic Development, Trade and Tourism; and the Ministry of Health, of the Government of Alberta. The Cumming Medical Research Fund also supported the analyses. …

Early Experience with Tarlatamab (T-Cell Engagers) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Canada: Lessons Learned and Implementation Strategies.

As bispecific T-cell engagers (TCEs) gain traction in the oncology treatment landscape, cancer centres must develop robust clinical pathways to ensure their safe and efficient delivery. Given the limited experience of the Canadian medical oncology community with TCEs, collecting and publishing early clinical experiences with these novel agents will be essential to inform best practices and support their safe and effective adoption across the broader Canadian oncology community. The approval of tarlatamab, the first-in-class delta-like ligand 3 (DLL3)-targeted TCE for extensive-stage small cell

Совпадение в полном тексте источника
… Province | Available Educational Materials Ontario | Treating cancer with T-cell engaging antibodies: What you need to know Alberta | Cancer Care Alberta: Information for patients/families bispecific antibodies British Columbia | SCCRS & SCICANS patient handout Bispecific antibodies patient letter Bispecific … days (2–6 days) Most likely to occur after the first two doses ICANS incidence All grades (Grades 3–4) | 9% (0%) | Median onset: 29.5 days Median duration: 33 days (1–93 days) Tocilizumab use | 5–10% | Appendix C Figure A2 Algorithm for initiation of tarlatamab at Cross Cancer Institute, Edmonton, Alberta …

Opioid Use at End-Of-Life Among Nova Scotia Patients With Cancer.

Purpose: To determine the factors associated with opioid analgesic prescriptions as measured by community pharmacy dispensations to all Nova Scotia (NS) patients with cancer at end-of-life from 2005 to 2009. Methods: The NS Cancer Registry and the NS Prescription Monitoring Program (NSPMP) were used to link Nova Scotians who had a cancer diagnosis and received a prescription for opioids in their last year of life (n = 6,186) from 2005 to 2009. The association of factors with opioid dispensations at end-of-life were determined (e.g., patient demographics, type of prescriber, type of cancer, and

Совпадение в полном тексте источника
… The morphine equivalents used for morphine, hydromorphone, codeine, and oxycodone were 1, 5 ( Alberta Cancer Board, 2001 ), 0.05 and 0.334, respectively. For fentanyl, 1 mg of drug was considered equivalent to 300 mg of morphine based on a 3-days supply. … References Alberta Cancer Board (2001). Alberta Hospice Palliative Care Resource Manual. 2nd ed. [cited 25 Jan 2022]. Available from: http://www.med.uottawa.ca/courses/totalpain/pdf/doc-17.PDF . Bandieri E., Romero M., Ripamonti C. I., Artioli F., Sichetti D., Fanizza C., et al. (2016). …

Concurrent evolution of cancer cachexia and heart failure: bilateral effects exist.

Cancer cachexia is defined as a multifactorial syndrome of involuntary weight loss characterized by an ongoing loss of skeletal muscle mass and progressive functional impairment. It is postulated that cardiac dysfunction/atrophy parallels skeletal muscle atrophy in cancer cachexia. Cardiotoxic chemotherapy may additionally result in cardiac dysfunction and heart failure in some cancer patients. Heart failure thus may be a consequence of either ongoing cachexia or chemotherapy-induced cardiotoxicity; at the same time, heart failure can result in cachexia, especially muscle wasting. Therefore, t

Совпадение в полном тексте источника
… Table 1 shows the prevalence of cardiac disorders in a population of 16,500 patients who died of cancer in Alberta, Canada, 1993–2000. … SMRKB is supported by the Alberta Innovates Health Solutions Graduate Studentship award. …

Bridging Perspectives: How Canadian Patients and Caregivers View Quality of Life in Multiple Myeloma Compared to Validated Instruments.

Background: Validated patient- and caregiver-reported outcome (PRO and CRO) questionnaires are widely used to assess quality of life (QoL) in multiple myeloma (MM). However, most were developed before recent therapeutic advances that have modified disease trajectories and may no longer fully reflect patients' and caregivers' experiences. Methods: A Canadian cross-sectional observational study was conducted in collaboration with the PROxy Network and Myeloma Canada. Patients with MM completed the EORTC QLQ-C30, EORTC QLQ-MY20, EQ-5D-5L, and ESAS-R questionnaires and caregivers of patients with

Совпадение в полном тексте источника
… 4.8) Self-employed | 15 (4.9) | 9 (8.7) Invalid/Sick Leave | 41 (13.4) | 3 (13.4) Type of Medical Insurance, n (%) | | Private | 127 (41.6) | - Public | 75 (24.6) | - Private and Public | 96 (31.5) | - Unknown | 7 (2.3) | - Province of Residence, n (%) | | British Columbia | 49 (16.1) | 16 (15.4) Alberta … Alberta Health Services (AHS) Edmonton Symptom Assessment System—Revised (ESAS-r)—Administration Manual. Alberta Health Services (AHS); Edmonton, AB, Canada: 2019. 24. Hui D., Bruera E. The Edmonton Symptom Assessment System 25 Years Later: Past, Present, and Future Developments. J. …

Profiling of Small Nucleolar RNAs by Next Generation Sequencing: Potential New Players for Breast Cancer Prognosis.

One of the most abundant, yet least explored, classes of RNA is the small nucleolar RNAs (snoRNAs), which are well known for their involvement in post-transcriptional modifications of other RNAs. Although snoRNAs were only considered to perform housekeeping functions for a long time, recent studies have highlighted their importance as regulators of gene expression and as diagnostic/prognostic markers. However, the prognostic potential of these RNAs has not been interrogated for breast cancer (BC). The objective of the current study was to identify snoRNAs as prognostic markers for BC. Small RN

Совпадение в полном тексте источника
… Local institutional research ethics committee (Health Research Ethics Board of Alberta: Cancer Committee) approved the study protocol. … Next generation sequencing (NGS) was performed at PlantBiosis Ltd (Lethbridge, Alberta, Canada; http://www.plantbiosis.com/ ). The data generated for the study was deposited in gene expression omnibus and the accession ID is GEO68085 . …

The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023.

BACKGROUND: Cancer is a leading cause of death globally. Accurate cancer burden information is crucial for policy planning, but many countries do not have up-to-date cancer surveillance data. To inform global cancer-control efforts, we used the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 framework to generate and analyse estimates of cancer burden for 47 cancer types or groupings by age, sex, and 204 countries and territories from 1990 to 2023, cancer burden attributable to selected risk factors from 1990 to 2023, and forecasted cancer burden up to 2050. METHODS: Ca

Совпадение в полном тексте источника
… E Lytvyak reports grants or contracts from University of Alberta, Advanz Pharma, WCB Alberta, and CPSA; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Alberta Obesity Society; Other financial or non-financial support from University of … Alberta and Alberta Health Services; outside the submitted work. …

Temporal trends in disease-specific causes of cardiovascular mortality amongst patients with cancer in the USA between 1999 and 2019.

AimsWe report disease-specific cardiovascular causes of mortality among cancer patients in the USA between 1999 and 2019, considering temporal trends by age, sex, and cancer site.Methods and resultsWe used the Multiple Cause of Death database, accessed through the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research resource. We included 629 308 decedents with cardiovascular disease (CVD) recorded as the primary cause of death and active malignancy listed as a contributing cause of death. We created disease-specific CVD categories and grouped cancers b

Совпадение в полном тексте источника
… Louis Kolman, Libin Cardiovascular Institute of Alberta, Calgary, AB, Canada. Robert J H Miller, Libin Cardiovascular Institute of Alberta, Calgary, AB, Canada. Ariel Roguin, Department of Cardiology, Hillel Yaffe Medical Center, Hadera, Israel. …

Cannabis in Hematology Survey Study (CHESS): A Longitudinal Investigation on Uses, Attitudes, and Outcomes of Cannabis Among Hematology Patients Undergoing Hematopoietic Stem Cell Transplant.

Cancer patients use cannabis for medicinal purposes; however, few studies have examined hematology patients' use of cannabis and no research to our knowledge has investigated the use of cannabis amongst hematology patients before and after hematopoietic stem cell transplant (HCT). The purpose of this longitudinal survey study was to assess aspects of cannabis use in patients who underwent HCT. Eligible patients (N = 30) completed two surveys before and 90 days following their HCT. The surveys inquired about several aspects of cannabis (e.g., rate of use, beliefs and attitudes, access to inform

Совпадение в полном тексте источника
… This study was reviewed and approved by the Health Research Ethics Board of Alberta Cancer (HREBA.CC-19-0461). … Institutional Review Board Statement This study was reviewed and approved by the Health Research Ethics Board of Alberta Cancer (HREBA.CC-19-0461, 20 January 2020). Informed Consent Statement Participants provided informed consent to use their data as part of this study. …

Understanding cancer survivors' reasons to medicate with cannabis: A qualitative study based on the theory of planned behavior.

BackgroundPrior to nonmedical cannabis legalization in Canada, individuals were only able to access cannabis legally through licensed producers with medical authorization. Now with an additional legal access system designed for nonmedical purposes, it is unclear what factors influence cancer survivors' decisions to medicate or not medicate cannabis as a complementary therapy to alleviate their cancer symptoms.MethodsWe recruited cancer survivors via social media. Interested individuals were purposively sampled to ensure maximization in terms of age, sex, and province of residence. Constructs o

Совпадение в полном тексте источника
… result in cancer survivors opting to medicate their cancer symptoms without guidance from health‐care providers. 12 However, there have been limited studies determining the frequency of cannabis use among cancer patients in Canada. 13 , 14 , 15 , 16 A 2017 survey of cancer patients in the province of Alberta … TABLE 1 Characteristics of the study sample | Count (%) Sex Male | 13 (39%) Female | 20 (61%) Current age (years) <30 | 5 (15%) 30‐44 | 9 (27%) 45‐64 | 10 (30%) > 65 | 9 (27%) Province of residence British Columbia | 9 (27%) Alberta | 6 (18%) Ontario | 10 (30%) Quebec | 2 (6%) New Brunswick | 1 (3%) …

Assisted Peritoneal Dialysis: A Feasibility and Quality Improvement Project.

Despite often offering a better quality of life than in-center hemodialysis, peritoneal dialysis (PD) at home can be challenging for many. From May 2021 to October 2024, we offered PD assistance at 2 home dialysis clinics in Dialysis Clinic, Inc, a mid-size national dialysis provider. Eligible patients could be incident to or established on PD, with anticipated need for either permanent or temporary assistance. Over 3 years, 6 patients received assisted PD. Three established PD patients needed assistance when their care partners were unavailable. Three other patients required assistance to ini

Совпадение в полном тексте источника
… Retrospective review of assisted peritoneal dialysis: The Alberta, Canada experience. Perit Dial Int. Published online February 6, 2025 doi: 10.1177/08968608251313680. 10. Adoukonou N.E., Boyer A., Lobbedez T., Bechade C., Lanot A. …

50th ESCP Symposium on Clinical Pharmacy, Polypharmacy and ageing - highly individualized, interprofessional, person-centered care : 19–21 October 2022, Prague, Czech Republic

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Current management of cancer pain in Italy: Expert opinion paper.

IntroductionChronic pain and breakthrough cancer pain (BTcP) have a high prevalence in all cancer types and cancer stages, combined with a significant physical, psychological, and economic burden. Despite efforts to improve appropriate management of cancer pain, a poor assessment and guilty undertreatment are still reported in many countries. The purpose of this expert opinion paper is to contribute to reduce and clarify these issues with a multidisciplinary perspective in order to share virtuous paths of care.MethodsCommon questions about cancer pain assessment and treatment were submitted to

Совпадение в полном тексте источника
… The alberta breakthrough pain assessment tool for cancer patients: a validation study using a delphi process and patient think-aloud interviews. J Pain Symptom Manag. 2008;35:136–52. 10.1016/j.jpainsymman.2007.03.016. Hagen NA, Stiles C, Nekolaichuk C, Biondo P, Carlson LE, Fisher K. et al. … The alberta breakthrough pain assessment tool for cancer patients: a validation study using a delphi process and patient think-aloud interviews. J Pain Symptom Manag. 2008;35:136–52. doi: 10.1016/j.jpainsymman.2007.03.016. [44] Webber K, Davies AN, Zeppetella G, Cowie MR. …

Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.

OBJECTIVE: Recent reports warn that the worldwide cell culture capacity is insufficient to fulfill the increasing demand for human protein d … hs), squat (18 months), and climb stairs (22 months), and patient 3 learned to sit unsupported. The Alberta Infant Motor Scale score for patients 2, 3, and 4 remained far below p5. Patient 1 followed the p5 of normal. CONCLUSION: Our study shows that a safe and effective medicine can be produced in the milk of mammals and encourages additional developmen …

Характеристики лиц с множественным склерозом, охватываемых государственной страховкой от наркотиков в Квебекской родильной компании.

ЦЕЛЬ: Люди, живущие с множественным склерозом, используют лекарства по нескольким признакам, однако мало что известно о том, что они употребляют по рецепту в Квебеке, в частности потому, что государственная система страхования от наркомании охватывает лишь часть населения. Мы сравнили характеристики тех, кто имеет государственную страховку от наркотиков, с теми, кто имеет частную страховку. МЕТОДЫ: В группе лиц, родившихся в 1970-1974 годах, мы идентифицировали лиц, страдающих множественным склерозом, путем применения проверенного алгоритма к административным данным о состоянии здоровья. К чис

Совпадение в полном тексте источника
… Whereas some provinces (e.g., Quebec) provide universal coverage through either a private or a public plan, other provinces (e.g., Alberta) ( Ayodele et al., 2022 ) have a partially covered population due to eligibility criteria ( Sutherland and Dinh, 2017 ). …

References

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Overview of the Alberta Kidney Disease Network. BMC Nephrol 2009; 10: 30. 244. Turin TC, Coresh J, Tonelli M et al. One-year change in kidney function is associated with an increased mortality risk. Am J Nephrol 2012; 36: 41–49. 245. Turin TC, Coresh J, Tonelli M et al. …

Изучение того, что имеет наибольшее значение для пациентов при повторном рефрактальном лечении нескольких миелом: канадский эксперимент по дискретному выбору пациентов, лиц, обеспечивающих уход, и врачей.

КОЛИЧЕСТВО: Возвращение/изъятие нескольких миелом (RRMM) оказывает значительное воздействие на качество жизни пациентов. В рамках этого исследования были изучены особенности лечения, характерные для RRMM в Канаде, при этом были сопоставлены параметры традиционных методов лечения с характеристиками химической антигенной рецепторной (CAR) T-клетокой терапии. Она была направлена на понимание предпочтений пациентов и того, каким образом те, кто ухаживает за больными, и специалисты в области здравоохранения (ХЦП) воспринимают эти предпочтения. МЕТОДЫ: Был проведен эксперимент по дискретному выбору

Совпадение в полном тексте источника
… ) Ethnicity a First Nations, Métis or Inuk (Inuit) b 3 (3%) 1 (2%) White 90 (92%) 41 (91%) South Asian 1 (1%) 2 (4%) Chinese 2 (2%) 0 (0%) Black 1 (1%) 0 (0%) Arab 1 (1%) 0 (0%) Japanese 1 (1%) 0 (0%) Prefer not to answer 2 (2%) 2 (4%) Province/territory living in British Columbia 18 (18%) 12 (26%) Alberta … or Inuk (Inuit) b | 3 (3%) | 1 (2%) White | 90 (92%) | 41 (91%) South Asian | 1 (1%) | 2 (4%) Chinese | 2 (2%) | 0 (0%) Black | 1 (1%) | 0 (0%) Arab | 1 (1%) | 0 (0%) Japanese | 1 (1%) | 0 (0%) Prefer not to answer | 2 (2%) | 2 (4%) Province/territory living in British Columbia | 18 (18%) | 12 (26%) Alberta …